IBDEI2FD ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,38740,1,3,0)
 ;;=3^Heart Failure,Diastolic,Chronic
 ;;^UTILITY(U,$J,358.3,38740,1,4,0)
 ;;=4^I50.32
 ;;^UTILITY(U,$J,358.3,38740,2)
 ;;=^5007245
 ;;^UTILITY(U,$J,358.3,38741,0)
 ;;=I50.42^^152^1985^36
 ;;^UTILITY(U,$J,358.3,38741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38741,1,3,0)
 ;;=3^Heart Failure,Systolic & Diastolic,Chronic
 ;;^UTILITY(U,$J,358.3,38741,1,4,0)
 ;;=4^I50.42
 ;;^UTILITY(U,$J,358.3,38741,2)
 ;;=^5007249
 ;;^UTILITY(U,$J,358.3,38742,0)
 ;;=I13.0^^152^1985^30
 ;;^UTILITY(U,$J,358.3,38742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38742,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,38742,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,38742,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,38743,0)
 ;;=I13.2^^152^1985^31
 ;;^UTILITY(U,$J,358.3,38743,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38743,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 5 Chr Kdny
 ;;^UTILITY(U,$J,358.3,38743,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,38743,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,38744,0)
 ;;=I13.10^^152^1985^32
 ;;^UTILITY(U,$J,358.3,38744,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38744,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,38744,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,38744,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,38745,0)
 ;;=I13.11^^152^1985^33
 ;;^UTILITY(U,$J,358.3,38745,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38745,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 5 Chr Kdny
 ;;^UTILITY(U,$J,358.3,38745,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,38745,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,38746,0)
 ;;=E03.9^^152^1985^43
 ;;^UTILITY(U,$J,358.3,38746,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38746,1,3,0)
 ;;=3^Hypothyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,38746,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,38746,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,38747,0)
 ;;=M54.5^^152^1985^46
 ;;^UTILITY(U,$J,358.3,38747,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38747,1,3,0)
 ;;=3^Low Back Pain
 ;;^UTILITY(U,$J,358.3,38747,1,4,0)
 ;;=4^M54.5
 ;;^UTILITY(U,$J,358.3,38747,2)
 ;;=^5012311
 ;;^UTILITY(U,$J,358.3,38748,0)
 ;;=C61.^^152^1985^47
 ;;^UTILITY(U,$J,358.3,38748,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38748,1,3,0)
 ;;=3^Malig Neopl Prostate
 ;;^UTILITY(U,$J,358.3,38748,1,4,0)
 ;;=4^C61.
 ;;^UTILITY(U,$J,358.3,38748,2)
 ;;=^267239
 ;;^UTILITY(U,$J,358.3,38749,0)
 ;;=F11.20^^152^1985^53
 ;;^UTILITY(U,$J,358.3,38749,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38749,1,3,0)
 ;;=3^Opioid Dependence,Uncomplicated
 ;;^UTILITY(U,$J,358.3,38749,1,4,0)
 ;;=4^F11.20
 ;;^UTILITY(U,$J,358.3,38749,2)
 ;;=^5003127
 ;;^UTILITY(U,$J,358.3,38750,0)
 ;;=M19.90^^152^1985^54
 ;;^UTILITY(U,$J,358.3,38750,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38750,1,3,0)
 ;;=3^Osteoarthritis,Unspec
 ;;^UTILITY(U,$J,358.3,38750,1,4,0)
 ;;=4^M19.90
 ;;^UTILITY(U,$J,358.3,38750,2)
 ;;=^5010853
 ;;^UTILITY(U,$J,358.3,38751,0)
 ;;=M85.80^^152^1985^55
 ;;^UTILITY(U,$J,358.3,38751,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38751,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,38751,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,38751,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,38752,0)
 ;;=M81.0^^152^1985^56
 ;;^UTILITY(U,$J,358.3,38752,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38752,1,3,0)
 ;;=3^Osteoporosis,Age-Related w/o Fx
